Personalized medicine in psoriasis: Developing a genomic classifier to predict histological response to Alefacept

BMC Dermatology

Volumn 10, Issue , 2010, Pages

  Suárez Fariñas, Mayte ^a   Shah, Kejal R ^a   Haider, Asifa S ^a   Krueger, James G ^a   Lowes, Michelle A ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; AMINE OXIDASE DOMAIN 2; CHLORIDE INTRACELLULAR CHANNEL PROTEIN 1; CYCLIC AMP RESPONSIVE ELEMENT MODULATOR; CYCLOPHILIN B; DOLICHYL DIPHOSPHOOLIGOSACCHARIDE PROTEIN GLYCOSYLTRANSFERASE; EUKARYOTIC TRANSLATION ELONGATION FACTOR 1 GAMMA; FERRITIN LIGHT POLYPEPTIDE; GENE PRODUCT; HISTONE DEACETYLASE 3; INTERFERON INDUCED PROTEIN 35; NEUROBLASTOMA BREAKPOINT FAMILY MEMBER 10; NLR FAMILY PYRIN DOMAIN CONTAINING 1; PHOSPHOLIPASE C BETA1; POU CLASS 2 HOMEOBOX 2; PROTEIN V MAF; PROTEIN WEE1; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE MITOCHONDRIAL F1 COMPLEX O SUBUNIT; PURINE RICH ELEMENT BINDING PROTEIN A; RANTES; SAM AND SH3 DOMAIN CONTAINING 3; SULFOTRANSFERASE FAMILY CYTOSOLIC 1A PHENOL PREFERRING MEMBER 1; SULFOTRANSFERASE FAMILY CYTOSOLIC 1A PHENOL PREFERRING MEMBER 3; TRANSCRIPTION FACTOR MAFF; TU TRANSLATION ELONGATION FACTOR MITOCHONDRIAL; UNCLASSIFIED DRUG; DERMATOLOGICAL AGENT; HYBRID PROTEIN;

ACANTHOSIS; ADULT; AGE DETERMINATION; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DISEASE CLASSIFICATION; DRUG ACTIVITY; ETHNICITY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PARAKERATOSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PSORIASIS; SEX DETERMINATION; SYMPTOMATOLOGY; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; DNA MICROARRAY; DRUG RESISTANCE; GENETICS; GENOMICS; HOSPITALIZATION; HUMAN GENOME; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PERSONALIZED MEDICINE; PREDICTION AND FORECASTING;

ADULT; AGED; DERMATOLOGIC AGENTS; DRUG RESISTANCE; FEMALE; GENOME, HUMAN; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PSORIASIS; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 77949436490     PISSN: None     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/1471-5945-10-1     Document Type: Article

References (21)

1. Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003, 49:S87-97. 10.1016/mjd.2003.552, 12894131.
2. Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski K, Krueger J. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 2005, 102:2075-2080. 10.1073/pnas.0409569102, 545584, 15671179.
3. Chamian F, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG, Lowes MA. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med 2007, 5:27. 10.1186/1479-5876-5-27, 1906741, 17555598.
4. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanisms of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/Function analysis in vitro and in human CD2 transgenic mice. Journal of Immunology 1994, 152:2753-2767.
5. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, Wallner BP. Specific interaction of lymphocyte function associated antigen 3 with CD2 can inhibit T cell responses. Journal of Experimental Medicine 1993, 178:211-222. 10.1084/jem.178.1.211, 2191085, 7686212.
6. Haider AS, Lowes MA, Gardner H, Bandaru R, Darabi K, Chamian F, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Novitskaya I, Krueger J. Novel insight into agonistic mechanism of alefacept in vivo: Differentially expressed genes may serve as biomarkers of response in psoriasis patients. Journal of Immunology 2007, 178:7442-7449.
7. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002, 99:6567-6572. 10.1073/pnas.082099299, 124443, 12011421.
8. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537. 10.1126/science.286.5439.531, 10521349.
9. Birkenkamp-Demtroder K, Christensen LL, Olesen SH, Frederiksen CM, Laiho P, Aaltonen LA, Laurberg S, Sorensen FB, Hagemann R, TF OR. Gene expression in colorectal cancer. Cancer Res 2002, 62:4352-4363.
10. Del Rio M, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P, Bareil C, Kramar A, Salvetat N, Fraslon C, Conseiller E, Granci V, Leblanc B, Pau B, Martineau P, Ychou M. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 2007, 25:773-780. 10.1200/JCO.2006.07.4187, 2257989, 17327601.
11. Liu H, Li N, Yao L, Jiang L, Bao G, Li J, Ma Q, Liu Z. Prediction of doxorubicin sensitivity in gastric cancers based on a set of novel markers. Oncol Rep 2008, 20:963-969.
12. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen H, Dorssers LC, Klijn JG, Berns EM. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005, 23:732-740. 10.1200/JCO.2005.05.145, 15681518.
13. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S, Kato K. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005, 23:422-431. 10.1200/JCO.2005.09.078, 15659489.
14. Koczan D, Drynda S, Hecker M, Drynda A, Guthke R, Kekow J, Thiesen HJ. Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 2008, 10:R50. 2483439, 18454843.
15. Suarez-Farinas M, Pellegrino M, Wittkowski KM, Magnasco MO. Harshlight: a "corrective make-up" program for microarray chips. BMC Bioinformatics 2005, 6:294. 10.1186/1471-2105-6-294, 1327692, 16336691.
16. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction 2009, New York: Springer-Verlag, Second.
17. Molina CA, Foulkes NS, Lalli E, Sassone-Corsi P. Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell 1993, 75:875-886. 10.1016/0092-8674(93)90532-U, 8252624.
18. Solomou EE, Juang YT, Gourley MF, Kammer GM, Tsokos GC. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol 2001, 166:4216-4222.
19. Inoue T, Kimura T, Azuma C, Inazawa J, Takemura M, Kikuchi T, Kubota Y, Ogita K, Saji F. Structural organization of the human oxytocin receptor gene. J Biol Chem 1994, 269:32451-32456.
20. Ye Z, Ting JP. NLR, the nucleotide-binding domain leucine-rich repeat containing gene family. Curr Opin Immunol 2008, 20:3-9.
21. Yoshie O, Imai T, Nomiyama H. Chemokines in immunity. Adv Immunol 2001, 78:57-110. full_text, 11432208.